Agenus

AGENPhase 3

Lexington, United StatesFounded 1994agenusbio.com

Agenus is focused on developing novel immunotherapies designed to overcome the limitations of first-generation checkpoint inhibitors, particularly in 'cold' or immunologically resistant tumors. The company's most advanced asset, the BOT/BAL combination, has shown promising activity in multiple solid tumors and is now entering registrational studies. With a 30-year legacy in immunotherapy, Agenus leverages a multi-faceted platform to create treatments that aim to deliver deeper and more durable responses for cancer patients.

Market Cap

$2.5B

Founded

1994

Focus

BiologicsVaccines

AGEN · Stock Price

USD 64.971.57 (-2.36%)

Historical price data

AI Company Overview

Technology Platform

Agenus's platform focuses on modulating the cancer immunity cycle through Fc-enhanced antibodies targeting CTLA-4, a suite of checkpoint modulators (PD-1, LAG-3, TIM-3, ILT2/4, etc.), an adjuvant platform (QS-21 STIMULON), and allogeneic cell therapy (iNKT cells).

Pipeline Snapshot

61 drugs in pipeline, 7 in Phase 3

Drug	Indication	Stage
Balstilimab + Botensilimab + Folfox Protocol + XELOX + Nivolumab	Gastric Cancer	Phase 3
HSPPC-96 or Oncophage	Malignant Melanoma	Phase 3
Balstilimab + Botensilimab	Colorectal Cancer	Phase 3
autologous human tumor-derived HSPPC-96	Renal Cell Carcinoma	Phase 3
HSPPC-96	Kidney Cancer	Phase 3

Opportunities

The primary growth opportunity is the successful development and approval of BOT/BAL for MSS colorectal cancer, a large, treatment-resistant population.

Further expansion into neoadjuvant settings across multiple tumor types and potential label expansions based on ongoing Phase 2 data present significant upside.

Royalties from partnered programs and the QS-21 adjuvant provide foundational revenue.

Risk Factors

Key risks include clinical failure of the pivotal Phase 3 trial for BOT/BAL, regulatory hurdles, intense competition in immuno-oncology, and the ongoing need for substantial capital to fund late-stage development and potential commercialization.

Competitive Landscape

Agenus competes with large pharma (BMS, Merck, Roche) and other biotechs in the crowded immuno-oncology space. Its main differentiation is the Fc-enhanced design of botensilimab, aiming for superior efficacy/safety versus first-gen CTLA-4 inhibitors, particularly in 'cold' tumors like MSS CRC where current immunotherapies have failed.

Company Info

TypeTherapeutics

Founded1994

LocationLexington, United States

StagePhase 3

RevenueEarly Revenue

Trading

TickerAGEN

ExchangeNASDAQ

Contact

agenusbio.com

Therapeutic Areas

Oncology

Partners

Merck (MK-4830 license)Incyte (INCAGN2390, INCAGN2385, INCAGN1876, INCAGN1949 licenses)Rottapharm Biotech (CR6086 collaboration)Canadian Cancer Trials Group (CCTG) (Phase 3 trial collaboration)AGITGPRODIGE/Unicancer/GERCOR/FFCD

SIMILAR COMPANIES